| Original language | English (US) |
|---|---|
| Pages (from-to) | 3321-3322 |
| Number of pages | 2 |
| Journal | Journal of Allergy and Clinical Immunology: In Practice |
| Volume | 9 |
| Issue number | 9 |
| DOIs | |
| State | Published - Sep 2021 |
Keywords
- COVID-19
- PEG
- SARS-CoV2 vaccine
- Sensitivity
- Shared decision-making
- Skin testing
- Specificity
- Vaccine reaction
ASJC Scopus subject areas
- Immunology and Allergy
Access to Document
Other files and links
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
In: Journal of Allergy and Clinical Immunology: In Practice, Vol. 9, No. 9, 09.2021, p. 3321-3322.
Research output: Contribution to journal › Editorial › peer-review
}
TY - JOUR
T1 - PEG/Polysorbate Skin Testing Has No Utility in the Assessment of Suspected Allergic Reactions to SARS-CoV-2 Vaccines
AU - Greenhawt, Matthew
AU - Shaker, Marcus
AU - Golden, David B.K.
N1 - Funding Information: Conflicts of interest: M. Greenhawt has served as a consultant for the Canadian Transportation Agency, Thermo Fisher, Intrommune, and Aimmune Therapeutics; is a member of physician/medical advisory boards for Aimmune Therapeutics, DBV Technologies, Sanofi/Genzyme, Genentech, Nutricia, Kaleo Pharmaceutical, Nestle, Acquestive, Allergy Therapeutics, Pfizer, US World Meds, Allergenis, Aravax, and Monsanto; is a member of the scientific advisory council for the National Peanut Board; has received honorarium for lectures from Thermo Fisher, Aimmune, DBV, Before Brands, multiple state allergy societies, the American College of Allergy Asthma and Immunology, the European Academy of Allergy and Clinical Immunology; is an associate editor for the Annals of Allergy, Asthma, and Immunology; and is a member of the Joint Taskforce on Allergy Practice Parameters. M. Shaker is a member of the Joint Taskforce on Allergy Practice Parameters; serves on the Editorial Board of the Journal of Food Allergy and the Annals of Allergy, Asthma, and Immunology. D. B. K. Golden has received speakers bureau honoraria from Genentech, Kaleo; clinical trial support from Genentech, Novartis, Pfizer (unrelated to vaccine/vaccine development), GSK, and Regeneron; consulting fees from Aquestive; and royalties from UpToDate (section editor).
PY - 2021/9
Y1 - 2021/9
KW - COVID-19
KW - PEG
KW - SARS-CoV2 vaccine
KW - Sensitivity
KW - Shared decision-making
KW - Skin testing
KW - Specificity
KW - Vaccine reaction
UR - http://www.scopus.com/inward/record.url?scp=85114008871&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85114008871&partnerID=8YFLogxK
U2 - 10.1016/j.jaip.2021.06.025
DO - 10.1016/j.jaip.2021.06.025
M3 - Editorial
C2 - 34393075
AN - SCOPUS:85114008871
SN - 2213-2198
VL - 9
SP - 3321
EP - 3322
JO - Journal of Allergy and Clinical Immunology: In Practice
JF - Journal of Allergy and Clinical Immunology: In Practice
IS - 9
ER -